Report cover image

Branded Generics Market -Global Trends and Forecasts(2025 to 2034)

Publisher Factview Research
Published Nov 02, 2025
Length 186 Pages
SKU # FAVR20572997

Description

Branded Generics Market Size And Forecast

According to Factview Research, Global Branded Generics Market was valued at USD 237.428 Billion in 2024 and is projected to reach USD 466.365 Billion by 2034, growing at a CAGR of 7.7% from 2025 to 2034.

Global Branded Generics Market Outlook

The key factor such as the growing number of patents expired and expiring for branded drugs is majorly expected to boost the growth of the Global branded generic market. Moreover, the rising incidents and population suffering from chronic diseases and disorders are further expected to propel the growth of the market. Furthermore, entry of new players, simple marketing authorization procedures, changing medicine practices, greater profit margin are some other factors fueling the market growth. However, huge competition from branded drugs and commodity generic products and lack of penetration associated with the number of generic drugs worldwide are the key factors that might hamper the market growth.

Global Branded Generics Market Competitive Landscape

The Global Branded Generics Market study report will provide a valuable insight with an emphasis on Global market including some of the major players such as ZydusCadila, Teva Pharmaceutical Industries Ltd, Dr. Reddys Laboratories Ltd., Mylan N.V., Hospira Inc., Valeant, Apotex Inc., GlaxoSmithKline Pharmaceuticals Limited, Sandoz, Lupin Pharmaceuticals, Inc.

Table of Contents

186 Pages
1 Introduction Of Global Branded Generics Market
1.1 Overview Of The Market
1.2 Scope Of Report
1.3 Assumptions
2 Executive Summary
3 Research Methodology Of Factview Research
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List Of Data Sources
4 Global Branded Generics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Branded Generics Market, By Application
5.1 Overview
5.2 Oncology
5.3 Cardiovascular Diseases
5.4 Diabetes
5.5 Neurology
5.6 Others
6 Global Branded Generics Market, By Drug Class
6.1 Overview
6.2 Alkylating Agents
6.3 Antimetabolites
6.4 Anti-hypertensive
6.5 Anti-psychotics
6.6 Anti-epileptic
6.7 Others
7 Global Branded Generics Market, By Consumption-type
7.1 Overview
7.2 Oral
7.3 Parenteral
7.4 Topical
7.5 Others
8 Global Branded Generics Market, By Distribution Channel
8.1 Overview
8.2 Hospital Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Others
9 Global Branded Generics Market, By Geography
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest Of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest Of Asia Pacific
9.5 Rest Of The World
9.5.1 Latin America
9.5.2 Middle East
10 Global Branded Generics Market Competitive Landscape
10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies
11 Company Profiles
11.1 Zyduscadila
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments
11.2 Teva Pharmaceutical Industries Ltd
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments
11.3 Dr. Reddys Laboratories Ltd.
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments
11.4 Mylan N.V.
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments
11.5 Hospira Inc.
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments
11.6 Valeant
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments
11.7 Apotex Inc.
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments
11.8 Glaxosmithkline Pharmaceuticals Limited
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments
11.9 Sandoz
11.9.1 Overview
11.9.2 Financial Performance
11.9.3 Product Outlook
11.9.4 Key Developments
11.10 Lupin Pharmaceuticals, Inc.
11.10.1 Overview
11.10.2 Financial Performance
11.10.3 Product Outlook
11.10.4 Key Developments
12 Appendix
12.1 Related Research
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.